Results 11 to 20 of about 3,829,242 (325)

Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental). [PDF]

BMC Psychiatry, 2019
BackgroundRecommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking.MethodThe French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental ...
Bennabi D, Yrondi A, Charpeaud T, Genty JB, Destouches S, Lancrenon S, Allaili N, Bellivier F, Bougerol T, Camus V, Doumy O, Dorey JM, Haesebaert F, Holtzmann J, Lançon C, Lefebvre M, Moliere F, Nieto I, Rabu C, Richieri R, Schmitt L, Stephan F, Vaiva G, Walter M, Leboyer M, El-Hage W, Aouizerate B, Haffen E, Llorca PM, Courtet P.   +29 more
europepmc   +2 more sources

Utility and validity of DISC1 mouse models in biological psychiatry. [PDF]

Neuroscience, 2016
We have seen an era of explosive progress in translating neurobiology into etiological understanding of mental disorders for the past 10–15 years. The discovery of Disrupted-in-schizophrenia 1 (DISC1) gene was one of major driving forces that have ...
Tomoda T, Sumitomo A, Jaaro-Peled H, Sawa A.   +3 more
europepmc   +2 more sources

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. [PDF]

World J Biol Psychiatry, 2018
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the ...
Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J, Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.   +61 more
europepmc   +2 more sources

Back to Basics: The Importance of Measurement Properties in Biological Psychiatry [PDF]

Neuroscience and Biobehavioral Reviews, 2021
Daniel P Moriarity, Lauren Alloy
exaly   +2 more sources

Disconnectionism in Biological Psychiatry. [PDF]

Biol Psychiatry, 2017
Alexander-Bloch AF.
europepmc   +3 more sources

Schizophrenia: a Narrative Review of Etiological and Diagnostic Issues [PDF]

Consortium Psychiatricum, 2022
BACKGROUND: Despite the fact that schizophrenia has already been described historically and researched for a long time, this disorder remains unclear and controversial in many respects, including its etiology, pathogenesis, classification, diagnosis, and
Sofia N. Oskolkova
doaj   +1 more source

Corrigendum to “Schizophrenia: a narrative review of etiological and diagnostic issues” (Consortium Psychiatricum, 2022, Volume 3, Issue 3, doi: 10.17816/CP132) [PDF]

Consortium Psychiatricum, 2023
There is an error occurred in the article Schizophrenia: a narrative review of etiological and diagnostic issues published in the Consortium Psychiatricum journal (Volume 3 Issue 3) by Sofia Oskolkova.
Sofia N. Oskolkova
doaj   +1 more source

Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce

World Journal of Biological Psychiatry, 2022
Objectives The therapeutic use of nutrient-based ‘nutraceuticals’ and plant-based ‘phytoceuticals’ for the treatment of mental disorders is common; however, despite recent research progress, there have not been any updated global clinical guidelines ...
J. Sarris, A. Ravindran, L. Yatham, W. Marx, J. Rucklidge, R. McIntyre, S. Akhondzadeh, F. Benedetti, Constanza Caneo, H. Cramer, Lachlan Cribb, M. de Manincor, O. Dean, A. Deslandes, M. Freeman, B. Gangadhar, B. Harvey, S. Kasper, J. Lake, A. Lopresti, Lin Lu, Najwa-Joelle Metri, D. Mischoulon, C. Ng, D. Nishi, R. Rahimi, S. Seedat, J. Sinclair, K. Su, Zhang-Jin Zhang, M. Berk   +30 more
semanticscholar   +1 more source

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders

World Journal of Biological Psychiatry, 2023
Objectives This 2023 update of the WFSBP guidelines for the pharmacological treatment of eating disorders (EDs) reflects the latest diagnostic and psychopharmacological progress and the improved WFSBP recommendations for the assessment of the level of ...
H. Himmerich, Y. Lewis, C. Conti, H. Mutwalli, A. Karwautz, J. M. Sjögren, María Mercedes Uribe Isaza, M. Tyszkiewicz-Nwafor, M. Aigner, S. McElroy, J. Treasure, S. Kasper, U. Bailer, C. Bulik, Chiara Conti, M. Zwaan, A. Favaro, F. Fernández-Aranda, S. Fetissov, A. Hilbert, H. Himmerich, H. Wijbrand Hoek, C. Kan, O. Karpenko, A. Karwautz, S. Kasper, W. Kaye, Y. Lewis, S. McElroy, James Mitchell, P. Monteleone, Sabrina Mörkl, D. Müller, H. Mutwalli, B. P. Nazar, H. Papežová, J. M. Sjögren, H. Steiger, Dan J Stein, C. P. Szabo, M. Tyszkiewicz-Nwafor, U. Voderholzer, María Mercedes Uribe Isaza, T. Wade, W. D. Wranik, K. Yoshiuchi   +45 more
semanticscholar   +1 more source

Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy

Frontiers in Neuroscience, 2021
As psychedelic compounds gain traction in psychiatry, there is a need to consider the active mechanism to explain the effect observed in randomized clinical trials.
Lauren Lepow, Lauren Lepow, Hirofumi Morishita, Hirofumi Morishita, Hirofumi Morishita, Rachel Yehuda, Rachel Yehuda   +6 more
doaj   +1 more source